How von Willebrand Diseases Medications Work

Von Willebrand disease is a genetic disorder that affects the blood's ability to clot. It is caused by a deficiency or dysfunction of the von Willebrand factor (VWF), a protein necessary for platelet adhesion and aggregation.

Gold Standard Treatment: Factor VIII Replacement Therapy

The gold standard treatment for von Willebrand disease is Factor VIII replacement therapy, which involves administering recombinant or plasma-derived Factor VIII concentrates to replace the deficient factor. This therapy works by:

• Replacing VWF and Factor VIII deficiencies: By providing a sufficient amount of these proteins, patients can achieve normal clotting function.

• Improving platelet adhesion and aggregation: The presence of VWF enables platelets to adhere to the site of injury, initiating the clotting process.

Alternative Treatments

For patients who cannot tolerate or respond to Factor VIII replacement therapy, alternative treatments are available:

• Desmopressin: A synthetic hormone that stimulates the release of VWF from storage sites in endothelial cells.

• Factor VIII inhibitor bypassing activity (FEIBA): A plasma-derived product that contains a mixture of coagulation factors, including Factor VIII inhibitors.

• Plasma-derived von Willebrand factor concentrate: A biological product derived from human plasma that contains VWF and other clotting factors.

These alternative treatments work by either stimulating the release of VWF or providing a source of VWF and other coagulation factors to replace the deficient proteins.